Red Cell Lysis Buffer Application Versus Conventional Sample Processing in EUS-FNB

Launched by CHANGHAI HOSPITAL · Jul 12, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to prepare tissue samples from patients with solid pancreatic lesions, which are abnormal growths in the pancreas that may need further examination. The researchers want to see if using a special solution called red cell lysis buffer (RCLB) can improve the quality of the tissue samples by reducing the amount of blood contamination compared to the usual method of using formalin solution. This is important because better quality samples can help doctors make more accurate diagnoses.

To participate in this trial, you need to be between 18 and 80 years old and have a solid pancreatic lesion that has been confirmed with imaging tests like CT or MRI. You will undergo a procedure called endoscopic ultrasound (EUS) to collect tissue samples, which will then be processed using both methods. The researchers will compare the samples to see if the RCLB method results in less blood contamination. It’s worth noting that some people may not be eligible if they have certain medical conditions or are currently involved in another clinical trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 to 80 years old; Solid pancreatic lesions confirmed by clinical and CT/MRI/ PET imaging. Signed written informed consent
• Exclusion Criteria:
• • Contraindication of EUS-guide procedure or technical infeasibility (e.g.,coagulation disorder, anatomical changes, large vessels along the puncture path) Pregnant Patient is enrolled in any other clinical protocol or investigational trial